| atezolizumab based treatment |
| atezolizumab plus carboplatin plus nab-paclitaxel |
| non squamous cell - mNSCLC - L1 | |
| non squamous - mNSCLC - L1 - all population 3 | |
| non squamous - mNSCLC - L1 - PDL1 positive | |
| non squamous - mNSCLC - L1 - Wild Type (WT) 6 | |
Comparator:
vs atezolizumab plus carboplatin plus nab-paclitaxel; vs carboplatin plus nab-paclitaxel;
Risk of bias:
low;
some concerns;
high;
NA;